{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:15:04Z","timestamp":1785237304737,"version":"3.55.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.cld.2018.03.005","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T19:03:33Z","timestamp":1526583813000},"page":"517-532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Understanding and Treating Pruritus in Primary Biliary Cholangitis"],"prefix":"10.1016","volume":"22","author":[{"given":"Andres F.","family":"Carrion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan D.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10003","key":"10.1016\/j.cld.2018.03.005_bib1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cld.2018.03.005_bib2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2018.03.005_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1542-3565(03)00134-4","article-title":"Natural history of pruritus in primary biliary cirrhosis","volume":"1","author":"Talwalkar","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2018.03.005_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.26909","article-title":"Pruritus in cholestasis: facts and fiction","volume":"60","author":"Beuers","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2018.03.005_bib5","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.cld.2018.03.005_bib6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1053\/j.gastro.2014.08.042","article-title":"The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice","volume":"147","author":"Lieu","year":"2014","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2018.03.005_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000440829","article-title":"Pathogenesis and management of pruritus in PBC and PSC","volume":"33","author":"Kremer","year":"2015","journal-title":"Dig Dis"},{"issue":"8","key":"10.1016\/j.cld.2018.03.005_bib8","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1113\/JP273961","article-title":"Lysophosphatidic acid-induced itch is mediated by signalling of LPA5 receptor, phospholipase D and TRPA1\/TRPV1","volume":"595","author":"Kittaka","year":"2017","journal-title":"J\u00a0Physiol"},{"issue":"4","key":"10.1016\/j.cld.2018.03.005_bib9","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.25748","article-title":"Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions","volume":"56","author":"Kremer","year":"2012","journal-title":"Hepatology"},{"issue":"19","key":"10.1016\/j.cld.2018.03.005_bib10","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.3748\/wjg.v23.i19.3418","article-title":"Recent advances in the management of pruritus in chronic liver diseases","volume":"23","author":"Tajiri","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2011.08.043","article-title":"Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids","volume":"147","author":"Liu","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.cld.2018.03.005_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000446011","article-title":"Central mechanisms of itch","volume":"50","author":"Carstens","year":"2016","journal-title":"Curr Probl Dermatol"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0168-0102(99)00070-X","article-title":"Itch-associated response induced by intradermal serotonin through 5-HT2 receptors in mice","volume":"35","author":"Yamaguchi","year":"1999","journal-title":"Neurosci Res"},{"issue":"1","key":"10.1016\/j.cld.2018.03.005_bib14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/JID.2015.388","article-title":"Involvement of TRPV4 in serotonin-evoked scratching","volume":"136","author":"Akiyama","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"issue":"12","key":"10.1016\/j.cld.2018.03.005_bib15","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1111\/j.1572-0241.2003.08662.x","article-title":"Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis","volume":"98","author":"Browning","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jaci.2016.12.980","article-title":"Substance P activates mas-related G protein-coupled receptors to induce itch","volume":"140","author":"Azimi","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1665-2681(19)31658-8","article-title":"Serum concentrations of substance P in cholestasis","volume":"9","author":"Trivedi","year":"2010","journal-title":"Ann Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2018.03.005_bib18","first-page":"509","article-title":"Antinociceptive effects of nociceptin\/orphanin FQ administered intrathecally in monkeys","volume":"10","author":"Ko","year":"2009","journal-title":"J\u00a0Pain"},{"issue":"13","key":"10.1016\/j.cld.2018.03.005_bib19","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1111\/bph.13124","article-title":"Supraspinal actions of nociceptin\/orphanin FQ, morphine and substance P in regulating pain and itch in non-human primates","volume":"172","author":"Ding","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cld.2018.03.005_bib20","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.biopha.2016.10.068","article-title":"Evidence for the involvement of nitric oxide in cholestasis-induced itch associated response in mice","volume":"84","author":"Ostadhadi","year":"2016","journal-title":"Biomed Pharmacother"},{"issue":"1\u20132","key":"10.1016\/j.cld.2018.03.005_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0014-2999(00)00773-1","article-title":"The role of nitric oxide in bradycardia of rats with obstructive cholestasis","volume":"411","author":"Nahavandi","year":"2001","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.cld.2018.03.005_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study","volume":"58","author":"Mells","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2018.03.005_bib23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.cld.2018.03.005_bib24","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","article-title":"Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses","volume":"102","author":"Gong","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.cld.2018.03.005_bib25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.cld.2018.03.005_bib26","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/00042737-199908000-00001","article-title":"Prescribing habits in primary biliary cirrhosis: a national survey","volume":"11","author":"Verma","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2018.03.005_bib27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2340\/00015555-0350","article-title":"Itch in primary biliary cirrhosis: a patients' perspective","volume":"88","author":"Rishe","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"10.1016\/j.cld.2018.03.005_bib28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/j.1552-4604.1993.tb01928.x","article-title":"Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis","volume":"33","author":"Simons","year":"1993","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.cld.2018.03.005_bib29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/j.1552-4604.1989.tb03424.x","article-title":"The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis","volume":"29","author":"Simons","year":"1989","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.cld.2018.03.005_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2018.03.005_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2018.03.005_bib32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJM196109072651004","article-title":"The treatment of pruritus and hypercholesteremia of primary biliary cirrhosis with cholestyramine","volume":"265","author":"Van Itallie","year":"1961","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2018.03.005_bib33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0016-5085(66)80071-9","article-title":"Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis","volume":"50","author":"Datta","year":"1966","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2018.03.005_bib34","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.1961.03040180034008","article-title":"Relief of the pruritus of jaundice with a bile-acid sequestering resin","volume":"176","author":"Carey","year":"1961","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cld.2018.03.005_bib35","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.23821","article-title":"The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kuiper","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib36","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial","volume":"94","author":"Ghent","year":"1988","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/BF01300759","article-title":"Treatment of pruritus of primary biliary cirrhosis with rifampin","volume":"36","author":"Podesta","year":"1991","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.cld.2018.03.005_bib38","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","article-title":"Effects of long-term rifampicin administration in primary biliary cirrhosis","volume":"102","author":"Bachs","year":"1992","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.cld.2018.03.005_bib39","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1478-3231.2006.01326.x","article-title":"Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials","volume":"26","author":"Khurana","year":"2006","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.cld.2018.03.005_bib40","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","article-title":"The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus","volume":"102","author":"Tandon","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cld.2012.11.006","article-title":"Advances in pathogenesis and treatment of pruritus","volume":"17","author":"Bolier","year":"2013","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cld.2018.03.005_bib42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.taap.2016.05.002","article-title":"Modulation of expression and activity of intestinal multidrug resistance-associated protein 2 by xenobiotics","volume":"303","author":"Tocchetti","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"10.1016\/j.cld.2018.03.005_bib43","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/gut.50.3.436","article-title":"Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis","volume":"50","author":"Prince","year":"2002","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.cld.2018.03.005_bib44","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1365-2125.2011.04158.x","article-title":"Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus","volume":"73","author":"Sampaziotis","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cld.2018.03.005_bib45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-0711-5-3","article-title":"Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor","volume":"5","author":"Chen","year":"2006","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"2 Pt 1","key":"10.1016\/j.cld.2018.03.005_bib46","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0190-9622(87)80324-9","article-title":"Toxic epidermal necrolysis due to rifampicin","volume":"17","author":"Okano","year":"1987","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6096","key":"10.1016\/j.cld.2018.03.005_bib47","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1136\/bmj.2.6096.1189","article-title":"Stevens-Johnson syndrome due to rifampicin","volume":"2","author":"Nyirenda","year":"1977","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.cld.2018.03.005_bib48","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/hep.510290450","article-title":"The pruritus of cholestasis","volume":"29","author":"Jones","year":"1999","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2018.03.005_bib49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-123-3-199508010-00001","article-title":"Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial","volume":"123","author":"Bergasa","year":"1995","journal-title":"Ann Intern Med"},{"issue":"3 Pt 1","key":"10.1016\/j.cld.2018.03.005_bib50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0190-9622(99)70117-9","article-title":"Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study","volume":"41","author":"Bergasa","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.cld.2018.03.005_bib51","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.510270307","article-title":"Open-label trial of oral nalmefene therapy for the pruritus of cholestasis","volume":"27","author":"Bergasa","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2018.03.005_bib52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ejp.766","article-title":"An evidence-based review of systemic treatments for itch","volume":"20","author":"Pongcharoen","year":"2016","journal-title":"Eur J Pain"},{"issue":"4","key":"10.1016\/j.cld.2018.03.005_bib53","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study","volume":"113","author":"Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2018.03.005_bib54","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","article-title":"Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study","volume":"37","author":"Terg","year":"2002","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib55","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0016-5085(03)00879-5","article-title":"Pain as a complication of use of opiate antagonists for symptom control in cholestasis","volume":"125","author":"McRae","year":"2003","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib56","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL clinical practice guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib57","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0016-5085(00)70225-3","article-title":"Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis","volume":"118","author":"Jones","year":"2000","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2018.03.005_bib58","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"10.1016\/j.cld.2018.03.005_bib59","first-page":"3","article-title":"The nature of the discontinuation syndrome associated with antidepressant drugs","volume":"67","author":"Shelton","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.cld.2018.03.005_bib60","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3949\/ccjm.83a.15129","article-title":"Serotonin syndrome: preventing, recognizing, and treating it","volume":"83","author":"Wang","year":"2016","journal-title":"Cleve Clin J Med"},{"issue":"8855","key":"10.1016\/j.cld.2018.03.005_bib61","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/0140-6736(93)91178-O","article-title":"Improvement of cholestatic pruritus by ondansetron","volume":"341","author":"Schworer","year":"1993","journal-title":"Lancet"},{"issue":"76","key":"10.1016\/j.cld.2018.03.005_bib62","first-page":"1196","article-title":"Ondansetron and pruritus in chronic liver disease: a controlled study","volume":"54","author":"Jones","year":"2007","journal-title":"Hepatogastroenterology"},{"issue":"10","key":"10.1016\/j.cld.2018.03.005_bib63","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00042737-199810000-00010","article-title":"Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial","volume":"10","author":"Muller","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2018.03.005_bib64","doi-asserted-by":"crossref","first-page":"e10968","DOI":"10.1371\/journal.pone.0010968","article-title":"Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy","volume":"5","author":"Stander","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.cld.2018.03.005_bib65","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/hep.21185","article-title":"Nasobiliary drainage for cholestatic pruritus","volume":"43","author":"Hofmann","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib66","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/apt.13449","article-title":"The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study","volume":"43","author":"Hegade","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.cld.2018.03.005_bib67","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/liv.13281","article-title":"Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch","volume":"37","author":"Krawczyk","year":"2017","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib68","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jhep.2010.02.031","article-title":"Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers","volume":"53","author":"Pares","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2018.03.005_bib69","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1111\/j.1600-6143.2011.03738.x","article-title":"Regional variability in symptom-based MELD exceptions: a response to organ shortage?","volume":"11","author":"Argo","year":"2011","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.cld.2018.03.005_bib70","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cld.2015.08.011","article-title":"Liver transplantation for cholestatic liver diseases in adults","volume":"20","author":"Khungar","year":"2016","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.cld.2018.03.005_bib71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","author":"Reig","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2018.03.005_bib72","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0168-8278(17)30442-7","article-title":"A\u00a02-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)","volume":"66","author":"Corpechot","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"8193","key":"10.1016\/j.cld.2018.03.005_bib73","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0140-6736(80)91849-8","article-title":"Phototherapy for pruritus in primary biliary cirrhosis","volume":"2","author":"Hanid","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2018.03.005_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-200634","article-title":"Refractory pruritus in primary biliary cirrhosis","volume":"2013","author":"Pinheiro","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib75","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2133.1987.tb05825.x","article-title":"A\u00a0combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis","volume":"116","author":"Cerio","year":"1987","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.cld.2018.03.005_bib76","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jhep.2012.04.023","article-title":"Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study","volume":"57","author":"Decock","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2018.03.005_bib77","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/j.1572-0241.2001.03778.x","article-title":"Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease","volume":"96","author":"Bergasa","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2018.03.005_bib78","doi-asserted-by":"crossref","first-page":"e0178991","DOI":"10.1371\/journal.pone.0178991","article-title":"Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses","volume":"12","author":"Kamimura","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.cld.2018.03.005_bib79","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/hepr.12830","article-title":"Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial","volume":"47","author":"Kumada","year":"2017","journal-title":"Hepatol Res"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2018.03.005_bib80","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.pain.2013.03.023","article-title":"Endocannabinoids: a unique opportunity to develop multitarget analgesics","volume":"154","author":"Maione","year":"2013","journal-title":"Pain"},{"issue":"8","key":"10.1016\/j.cld.2018.03.005_bib81","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/j.1572-0241.2002.05852.x","article-title":"Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease","volume":"97","author":"Neff","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2018.03.005_bib82","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1194\/jlr.R900012-JLR200","article-title":"Bile acid transporters","volume":"50","author":"Dawson","year":"2009","journal-title":"J\u00a0Lipid Res"},{"issue":"9","key":"10.1016\/j.cld.2018.03.005_bib83","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/gut.52.9.1371","article-title":"Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration","volume":"52","author":"Lanzini","year":"2003","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2018.03.005_bib84","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1016\/S0168-8278(16)00146-X","article-title":"CLARITY: a phase 2, randomized, double-blind, placebo-controlled study of lopixibat chloride (formerly LUM001) in the treatment of primary biliary cirrhosis associated with itching","volume":"64","author":"Mayo","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2018.03.005_bib85","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2015.10.024","article-title":"Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis","volume":"64","author":"Baghdasaryan","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"10074","key":"10.1016\/j.cld.2018.03.005_bib86","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326118300308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326118300308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T01:23:17Z","timestamp":1571361797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326118300308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1089326118300308"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2018.03.005","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding and Treating Pruritus in Primary Biliary Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2018.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}